GC
GCTK.US GlucoTrack Inc
- Market cap
- USD 257K
- P/E
- -
- P/B
- 0.65x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is GCTK.US undervalued?
Graham numberThe Graham number of GlucoTrack Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
GlucoTrack Inc fundamental analysis
No fundamental analysis for GlucoTrack Inc yet.
GlucoTrack Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About GlucoTrack Inc
GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, In…
Full company profileGlucoTrack Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
GlucoTrack Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 612K | 589K | 43.5K | 208K | 70.8K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 552K | 449K | -52.1K | 208K | -47.0K | -42.0K | -23.0K | -13.0K | -36.0K | - | -86.0K |
| Operating Income | 5.66M | 10.6M | 6.54M | 3.51M | -3.13M | -4.04M | -4.43M | -7.10M | -14.5M | -16.1M | -15.2M |
| EBITDA | -5.33M | -10.2M | -6.64M | -3.46M | -3.09M | -3.94M | -4.41M | -7.08M | -21.9M | -19.3M | -16.2M |
| Net Income | -5.41M | -10.3M | -6.72M | -3.52M | -2.70M | -4.07M | -4.44M | -7.10M | -22.6M | -19.4M | -16.3M |
| EPS | -12 | -21 | -10 | -443 | -268 | -395 | -860 | -1,026 | -1,823 | -647 | -147 |
| Balance Sheet | |||||||||||
| Total Assets | 2.46M | 1.67M | 688K | 1.10M | 10.6M | 6.27M | 2.44M | 4.91M | 5.93M | 7.84M | 1.50M |
| Total Liabilities | 13.4M | 18.2M | 3.56M | 2.51M | 1.62M | 1.11M | 1.21M | 1.71M | 18.9M | 5.01M | 3.24M |
| Shareholders' Equity | -10.9M | -16.6M | -2.87M | -1.41M | 8.98M | 5.16M | 1.23M | 3.20M | -13.0M | 2.83M | -1.74M |
| Cash & Short-term Investments | 149K | 53.8K | 97.1K | 419K | 9.82M | 6.06M | 2.31M | 4.49M | 5.62M | 7.38M | 1.12M |
| Total Debt | 162K | 183K | 168K | 378K | 363K | 250K | 195K | 196K | 267K | 33.0K | 19.0K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -5.31M | -5.90M | -4.89M | -3.90M | -3.50M | -3.77M | -3.73M | -6.56M | -12.5M | -15.2M | -15.3M |
| Capital Expenditure | 76.5K | 19.5K | 5.37K | 23.4K | 53.0K | 5.00K | 1.00K | 0.00 | 104K | 96.0K | 0.00 |
| Free Cash Flow | -5.39M | -5.91M | -4.90M | -3.92M | -3.55M | -3.77M | -3.73M | -6.56M | -12.6M | -15.3M | -15.3M |
| Ratios | |||||||||||
| ROE | - | - | - | - | -30.0% | -78.9% | -360.6% | -222.0% | - | -685.6% | - |
| ROA | -219.8% | -618.9% | -975.8% | -320.8% | -25.4% | -64.9% | -181.9% | -144.7% | -380.9% | -247.4% | -1,090.0% |
| Net Profit Margin | -884.4% | -1,752.2% | -15,442.0% | -1,690.4% | -3,809.1% | - | - | - | - | - | - |
| Debt to Equity | - | - | - | - | 0.04x | 0.05x | 0.16x | 0.06x | - | 0.01x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
GlucoTrack Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | USD 5.73K | 0.01 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:2 on Oct 26, 2026.
Who owns GlucoTrack Inc
- Insiders 3.30%
- Institutions 6.88%
- Public & others 89.83%
- Shares outstanding 1.18M
- Free float 341K
Top funds holding GCTK.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 4.77K | 0.20% | +0.02% | Sep 2026 |
Top institutions holding GCTK.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| HRT FINANCIAL LLC | 205K | 1.35% | +405.63% | Jun 2026 |
| Jane Street Group LLC | 128K | 0.84% | 0.00% | Jun 2026 |
| Ikarian Capital, LLC | 45.8K | 0.30% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 34.2K | 0.22% | -27.22% | Jun 2026 |
| Virtu Financial LLC | 18.7K | 0.12% | 0.00% | Jun 2026 |
| GRANITE ISLANDS PRIVATE WEALTH, LLC | 15.7K | 0.10% | 0.00% | Jun 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 13.5K | 0.09% | 0.00% | Jun 2026 |
| UBS Group AG | 13.3K | 0.09% | +1,800.71% | Jun 2026 |
| Citigroup Inc | 12.9K | 0.08% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 10.5K | 0.07% | 0.00% | Jun 2026 |
| ALERUS FINANCIAL NA | 4.00K | 0.03% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 3.44K | 0.02% | 0.00% | Jun 2026 |
| Barclays PLC | 1.26K | 0.01% | 0.00% | Jun 2026 |
| PlanVest Financial, Inc | 1.00K | 0.01% | 0.00% | Jun 2026 |
| Tradewinds Capital Management, LLC | 50.00 | 0.00% | 0.00% | Jun 2026 |
| Newbridge Financial Services Group, Inc. | 34.00 | 0.00% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 9.00 | 0.00% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 0.00 | 0.00% | -100.00% | Jun 2026 |
GlucoTrack Inc company profile
- Company name
- GlucoTrack Inc
- Ticker
- GCTK.US
- Exchange
- USA Stocks
- Listed since
- Apr 25, 2013
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 15
- Fiscal year end
- December
- Address
- 301 Route 17 North, Rutherford, NJ, United States, 07070
- Phone
- 201 842 7715
- Website
- glucotrack.com
About GlucoTrack Inc
GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.
GlucoTrack Inc management
7- Dr. Paul V. Goode Ph.D.Chief Technical Officer & President · born 1968
- Mr. Erik C. EmersonCEO & Director · born 1971
- Mr. Avner Gal MBA, MSc.EECo-Founder, Chairman Emeritus & Consultant · born 1954
- Mr. David Malka BACo-Founder · born 1965
- Mr. Vincent WongChief Operations Officer
- Dr. Mark Tapsak Ph.D.Chief Scientific Officer · born 1969
- Ms. Drinda BenjaminChief Commercial Officer · born 1976